BeOne Medicines (ONC) Stock Forecast & Price Target

Compare

813 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ONC Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

BeOne

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ONC Stock 12 Month Forecast

Average Price Target

$358.96

▲(2.23% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is $358.96 with a high forecast of $399.00 and a low forecast of $345.00. The average price target represents a 2.23% change from the last price of $351.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"183":"$183","400":"$400","237.25":"$237.3","291.5":"$291.5","345.75":"$345.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":399,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$399.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":358.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$358.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":345,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$345.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[183,237.25,291.5,345.75,400],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,332.04,337.19076923076926,342.3415384615385,347.4923076923077,352.64307692307693,357.7938461538462,362.9446153846154,368.0953846153846,373.24615384615385,378.3969230769231,383.54769230769233,388.6984615384615,393.84923076923076,{"y":399,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,332.04,334.1107692307692,336.1815384615385,338.2523076923077,340.32307692307694,342.39384615384614,344.4646153846154,346.5353846153846,348.60615384615386,350.67692307692306,352.7476923076923,354.8184615384615,356.8892307692307,{"y":358.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,332.04,333.0369230769231,334.0338461538462,335.03076923076924,336.02769230769235,337.0246153846154,338.02153846153846,339.01846153846157,340.0153846153846,341.0123076923077,342.0092307692308,343.00615384615384,344.00307692307695,{"y":345,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":191.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":224.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$399.00

Average Price Target$358.96

Lowest Price Target$345.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Reni Benjamin

Citizens JMP

$348

Buy

-0.89%

Downside

Reiterated

09/09/25

Citizens JMP Sticks to Its Buy Rating for BeOne Medicines (ONC)Citizens JMP reiterated a Market Outperform rating and $348.00 price target on BeOne Medicines (NASDAQ: ONC).

Owen Dosehart

TR | OpenAI - 4o

$332→$349

Hold

-0.61%

Downside

Reiterated

09/03/25

AI Generated ArticleAI Generated Article

Michael Schmidt

Guggenheim

$365

Buy

3.95%

Upside

Reiterated

08/29/25

Guggenheim Keeps Their Buy Rating on BeOne Medicines (ONC)

Yigal Nochomovitz

Citi

$399

Buy

13.63%

Upside

Assigned

08/29/25

Optimistic Buy Rating for BeOne Medicines Driven by Promising Sonrotoclax Trial Results and Market Potential

Jill Wu

CMB International Securities

$359.47

Buy

2.38%

Upside

Reiterated

08/08/25

Analysts' Top Healthcare Picks: Eli Lilly & Co (LLY), BeOne Medicines (ONC)

Leonid Timashev

RBC Capital

$349→$364

Buy

3.67%

Upside

Reiterated

08/08/25

RBC Capital Remains a Buy on BeOne Medicines (ONC)

Andrew Berens

Leerink Partners

$334→$345

Buy

-1.75%

Downside

Reiterated

08/07/25

BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Sean Laaman

Morgan Stanley

$330→$350

Buy

-0.32%

Downside

Reiterated

08/07/25

Morgan Stanley Sticks to Their Buy Rating for BeOne Medicines (ONC)

David Li

Bank of America Securities

$300→$350

Buy

-0.32%

Downside

Reiterated

08/07/25

BeOne Medicines: Strong Financial Performance and Strategic Positioning Justify Buy Rating

Unknown Analyst

UBS

Not Ranked

UBS

$326→$373

Buy

6.23%

Upside

Reiterated

08/07/25

UBS Sticks to Its Buy Rating for BeOne Medicines (ONC)

Yaron Werber

TD Cowen

$334→$360

Buy

2.53%

Upside

Reiterated

08/06/25

BeOne Medicines: Strong Financial Performance and Promising Pipeline Justify Buy Rating and Increased Price Target

Jessica Fye

J.P. Morgan

$321→$345

Buy

-1.75%

Downside

Reiterated

07/17/25

BeOne Medicines price target raised to $345 from $321 at JPMorganBeOne Medicines price target raised to $345 from $321 at JPMorgan

Rebecca Liang

Bernstein

―

Hold

―

Reiterated

06/05/25

Bernstein Reaffirms Their Hold Rating on BeiGene (ONC)

Tony Ren

Macquarie

$259→$313

Buy

-10.86%

Downside

Reiterated

02/28/25

BeiGene price target raised to $313 from $259 at MacquarieBeiGene price target raised to $313 from $259 at Macquarie

Kelly Shi

Jefferies

$286

Buy

-18.55%

Downside

Reiterated

02/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), BeiGene (NASDAQ: ONC) and AptarGroup (NYSE: ATR)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Reni Benjamin

Citizens JMP

$348

Buy

-0.89%

Downside

Reiterated

09/09/25

Citizens JMP Sticks to Its Buy Rating for BeOne Medicines (ONC)Citizens JMP reiterated a Market Outperform rating and $348.00 price target on BeOne Medicines (NASDAQ: ONC).

Owen Dosehart

TR | OpenAI - 4o

$332→$349

Hold

-0.61%

Downside

Reiterated

09/03/25

AI Generated ArticleAI Generated Article

Michael Schmidt

Guggenheim

$365

Buy

3.95%

Upside

Reiterated

08/29/25

Guggenheim Keeps Their Buy Rating on BeOne Medicines (ONC)

Yigal Nochomovitz

Citi

$399

Buy

13.63%

Upside

Assigned

08/29/25

Optimistic Buy Rating for BeOne Medicines Driven by Promising Sonrotoclax Trial Results and Market Potential

Jill Wu

CMB International Securities

$359.47

Buy

2.38%

Upside

Reiterated

08/08/25

Analysts' Top Healthcare Picks: Eli Lilly & Co (LLY), BeOne Medicines (ONC)

Leonid Timashev

RBC Capital

$349→$364

Buy

3.67%

Upside

Reiterated

08/08/25

RBC Capital Remains a Buy on BeOne Medicines (ONC)

Andrew Berens

Leerink Partners

$334→$345

Buy

-1.75%

Downside

Reiterated

08/07/25

BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Sean Laaman

Morgan Stanley

$330→$350

Buy

-0.32%

Downside

Reiterated

08/07/25

Morgan Stanley Sticks to Their Buy Rating for BeOne Medicines (ONC)

David Li

Bank of America Securities

$300→$350

Buy

-0.32%

Downside

Reiterated

08/07/25

BeOne Medicines: Strong Financial Performance and Strategic Positioning Justify Buy Rating

Unknown Analyst

UBS

Not Ranked

UBS

$326→$373

Buy

6.23%

Upside

Reiterated

08/07/25

UBS Sticks to Its Buy Rating for BeOne Medicines (ONC)

Yaron Werber

TD Cowen

$334→$360

Buy

2.53%

Upside

Reiterated

08/06/25

BeOne Medicines: Strong Financial Performance and Promising Pipeline Justify Buy Rating and Increased Price Target

Jessica Fye

J.P. Morgan

$321→$345

Buy

-1.75%

Downside

Reiterated

07/17/25

BeOne Medicines price target raised to $345 from $321 at JPMorganBeOne Medicines price target raised to $345 from $321 at JPMorgan

Rebecca Liang

Bernstein

―

Hold

―

Reiterated

06/05/25

Bernstein Reaffirms Their Hold Rating on BeiGene (ONC)

Tony Ren

Macquarie

$259→$313

Buy

-10.86%

Downside

Reiterated

02/28/25

BeiGene price target raised to $313 from $259 at MacquarieBeiGene price target raised to $313 from $259 at Macquarie

Kelly Shi

Jefferies

$286

Buy

-18.55%

Downside

Reiterated

02/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), BeiGene (NASDAQ: ONC) and AptarGroup (NYSE: ATR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines

1 Month

xxx

Success Rate

7/12 ratings generated profit

Average Return

+3.57%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +3.57% per trade.

3 Months

xxx

Success Rate

9/15 ratings generated profit

Average Return

+5.90%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.90% per trade.

1 Year

Kelly ShiJefferies

Success Rate

14/14 ratings generated profit

Average Return

+42.19%

reiterated a buy rating 7 months ago

Copying Kelly Shi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +42.19% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+86.43%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +86.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONC Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ONC has received 16 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. ONC average Analyst price target in the past 3 months is 358.96.

Each month's total comprises the sum of three months' worth of ratings.

ONC Financial Forecast

ONC Earnings Forecast

Next quarter’s earnings estimate for ONC is $0.67 with a range of $0.16 to $1.75. The previous quarter’s EPS was $0.91. ONC beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.13% of the time in the same period. In the last calendar year ONC has Preformed in-line its overall industry.

ONC Sales Forecast

Next quarter’s sales forecast for ONC is $1.36B with a range of $1.32B to $1.39B. The previous quarter’s sales results were $1.32B. ONC beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.12% of the time in the same period. In the last calendar year ONC has Preformed in-line its overall industry.

ONC Stock Forecast FAQ

What is ONC’s average 12-month price target, according to analysts?

Based on analyst ratings, BeOne Medicines’s 12-month average price target is 358.96.

What is ONC’s upside potential, based on the analysts’ average price target?

BeOne Medicines has 2.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ONC a Buy, Sell or Hold?

BeOne Medicines has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is BeOne Medicines’s price target?

The average price target for BeOne Medicines is 358.96. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $399.00 ,the lowest forecast is $345.00. The average price target represents 2.23% Increase from the current price of $351.13.

What do analysts say about BeOne Medicines?

BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of ONC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BeOne Medicines (ONC) Stock Forecast & Price Target

ONC Analyst Ratings

ONC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BeOne Medicines

ONC Analyst Recommendation Trends

ONC Financial Forecast

ONC Earnings Forecast

ONC Sales Forecast

ONC Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts